We found that the lack of therapeutic response observed was not due to insufficient antigen presentation by the tumor cells, as reexpression of the epigenetically silenced H2-Kb by treatment with the DNA methyltransferase inhibitor decitabine in these cells did not improve responses to MRTX + PD1 (fig. Here, PDCD1 is linked to neoplasm.